JP2008527041A5 - - Google Patents

Download PDF

Info

Publication number
JP2008527041A5
JP2008527041A5 JP2007552198A JP2007552198A JP2008527041A5 JP 2008527041 A5 JP2008527041 A5 JP 2008527041A5 JP 2007552198 A JP2007552198 A JP 2007552198A JP 2007552198 A JP2007552198 A JP 2007552198A JP 2008527041 A5 JP2008527041 A5 JP 2008527041A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007552198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/001483 external-priority patent/WO2006078598A2/en
Publication of JP2008527041A publication Critical patent/JP2008527041A/ja
Publication of JP2008527041A5 publication Critical patent/JP2008527041A5/ja
Withdrawn legal-status Critical Current

Links

JP2007552198A 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤 Withdrawn JP2008527041A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64493405P 2005-01-19 2005-01-19
PCT/US2006/001483 WO2006078598A2 (en) 2005-01-19 2006-01-13 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2008527041A JP2008527041A (ja) 2008-07-24
JP2008527041A5 true JP2008527041A5 (enExample) 2009-02-26

Family

ID=36692770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552198A Withdrawn JP2008527041A (ja) 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤

Country Status (7)

Country Link
US (1) US20090124641A1 (enExample)
EP (1) EP1855685A4 (enExample)
JP (1) JP2008527041A (enExample)
CN (1) CN101106998A (enExample)
AU (1) AU2006206675A1 (enExample)
CA (1) CA2593166A1 (enExample)
WO (1) WO2006078598A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068890A1 (es) * 2007-11-07 2009-12-16 Schering Corp Compuestos para inhibir la actividad quinesina ksp
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113549000A (zh) * 2020-04-23 2021-10-26 复旦大学 用于预防或治疗脂质代谢相关疾病的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20070149500A1 (en) * 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法

Similar Documents

Publication Publication Date Title
JP2008527038A5 (enExample)
Ruch et al. Hedgehog signaling pathway and cancer therapeutics: progress to date
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2009514881A5 (enExample)
JP2022017295A5 (enExample)
Sahebjam et al. The utility of hedgehog signaling pathway inhibition for cancer
JP2007517071A5 (enExample)
EP4161511A1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
JP2018504418A5 (enExample)
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
Jin et al. Curaxin CBL0137 exerts anticancer activity via diverse mechanisms
JP7182304B2 (ja) インドリノン化合物の使用
JP2009541223A5 (enExample)
RU2008122048A (ru) Аминопиримины в качестве ингибиторов киназ
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2002120515A (ru) Гетероциклические соединения, содержащие сульфонамидные группы
JP2015520753A5 (enExample)
Abdelaleem et al. Prospects for repurposing CNS drugs for cancer treatment.
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
Dai et al. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents
JP2008527041A5 (enExample)
JP2008527039A5 (enExample)
JP2020523354A5 (enExample)
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
JPWO2020163823A5 (enExample)